These drugs mimic the effects of a hormone called GLP-1, which is produced in the intestines in response to food intake
GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and a growing pipeline of new entrants are being prescribed to tens of millions of Americans for weight loss and diabetes management, and they are fundamentally altering how, when, and how much people eat
In contrast, Wegovy (semaglutide) is FDA-approved for weight loss, and Ozempic (semaglutide) is FDA-approved for type 2 diabetes but can also be prescribed off-label for weight loss at a providers discretion
Microdosing GLP-1 medications may be ideal for individuals looking for a gentle on-ramp to metabolic support, those with mild weight concerns, early-stage insulin resistance, or who are prioritizing sustainable lifestyle shifts alongside pharmaceutical guidance, says Dr